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Abstract: AIMS Female sex is considered an independent risk factor of transvenous leads extraction
(TLE) procedure. The aim of the study was to evaluate the effectiveness of TLE in women compared
with men. METHODS AND RESULTS A post hoc analysis of risk factors and effectiveness of TLE
in women and men included in the ESC-EHRA EORP ELECTRa registry was conducted. The rate of
major complications was 1.96% in women vs. 0.71% in men; P = 0.0025. The number of leads was higher
in men (mean 1.89 vs. 1.71; P < 0.0001) with higher number of abandoned leads in women (46.04% vs.
34.82%; P < 0.0001). Risk factors of TLE differed between the sexes, of which the major were: signs and
symptoms of venous occlusion [odds ratio (OR) 3.730, confidence interval (CI) 1.401-9.934; P = 0.0084],
cumulative leads dwell time (OR 1.044, CI 1.024-1.065; P < 0.001), number of generator replacements
(OR 1.029, CI 1.005-1.054; P = 0.0184) in females and the number of leads (OR 6.053, CI 2.422-15.129;
P = 0.0001), use of powered sheaths (OR 2.742, CI 1.404-5.355; P = 0.0031), and white blood cell count
(OR 1.138, CI 1.069-1.212; P < 0.001) in males. Individual radiological and clinical success of TLE
was 96.29% and 98.14% in women compared with 98.03% and 99.21% in men (P = 0.0046 and 0.0098).
CONCLUSION The efficacy of TLE was lower in females than males, with a higher rate of periprocedural
major complications. The reasons for this difference are probably related to disparities in risk factors
in women, including more pronounced leads adherence to the walls of the veins and myocardium. Lead
management may be key to the effectiveness of TLE in females.
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Aims Female sex is considered an independent risk factor of transvenous leads extraction (TLE) procedure. The aim of




A post hoc analysis of risk factors and effectiveness of TLE in women and men included in the ESC-EHRA EORP
ELECTRa registry was conducted. The rate of major complications was 1.96% in women vs. 0.71% in men;
P=0.0025. The number of leads was higher in men (mean 1.89 vs. 1.71; P<0.0001) with higher number of aban-
doned leads in women (46.04% vs. 34.82%; P<0.0001). Risk factors of TLE differed between the sexes, of which
the major were: signs and symptoms of venous occlusion [odds ratio (OR) 3.730, confidence interval (CI) 1.401–
9.934; P=0.0084], cumulative leads dwell time (OR 1.044, CI 1.024–1.065; P<0.001), number of generator
replacements (OR 1.029, CI 1.005–1.054; P=0.0184) in females and the number of leads (OR 6.053, CI 2.422–
15.129; P=0.0001), use of powered sheaths (OR 2.742, CI 1.404–5.355; P=0.0031), and white blood cell count
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(OR 1.138, CI 1.069–1.212; P<0.001) in males. Individual radiological and clinical success of TLE was 96.29% and
98.14% in women compared with 98.03% and 99.21% in men (P=0.0046 and 0.0098).
...................................................................................................................................................................................................
Conclusion The efficacy of TLE was lower in females than males, with a higher rate of periprocedural major complications.
The reasons for this difference are probably related to disparities in risk factors in women, including more pro-
nounced leads adherence to the walls of the veins and myocardium. Lead management may be key to the effective-
ness of TLE in females.
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Introduction
The progress in clinical pacing starting in the second half of the 20th
century has led to a rise in the number of patients with cardiac im-
plantable electronic devices (CIED). This rise in the device implanta-
tion rates translates into increased need for reoperation due to
changes in pacing mode, device infection, or lead dysfunction.
According to the report of 2017, there are over 9000 lead extrac-
tions performed annually in Europe, which corresponds to an aver-
age of 15 extraction procedures per million inhabitants.1 Women
and men undergoing transvenous lead extraction (TLE) differ in re-
gard to indications for CIED implantation and referral for TLE.
Electrophysiological observations show that sick sinus syndrome and
atrial fibrillation, are the most common indications for device implant
in women, whereas in men is atrioventricular block, which means
that dual-chamber devices are more common in men.2–4 It is also
known that less women than men receive implantable cardioverter-
defibrillator (ICD) and cardiac resynchronization therapy (CRT) devi-
ces despite their documented efficacy in both sexes.5,6 Several stud-
ies show a higher rate of early periprocedural complications in
female patients: pneumothorax, pocket haematomas, and lead perfo-
ration.2,7,8 Similarly, some reports demonstrate that TLE procedure
can be less effective in women.9–12 Preliminary analysis of the
European Cardiac Society (ESC) EURObservational Research
Programme (EORP) ELECTRa registry showed that female sex is an
independent risk factor for major complications during or immedi-
ately after TLE [odds ratio (OR) 2.11, 95% confidence interval 1.23–
3.62; P=0.0067].13 The present study was undertaken to provide an
in-depth analysis of the efficacy and safety of TLE in women and men
and to evaluate risk factors for the procedure in females and males.
Methods
Study population
Clinical data for analysis were obtained from ESC EORP ELECTRa regis-
try which encompassing included 76 centres from 19 European countries
and including 3555 patients (72.2% men) undergoing TLE between
November 2012 and May 2014. Leads characteristics were calculated on
the population of 3510 patients: 971 (27.7%) women and 2539 (72.3%)
men who underwent the intervention. The Executive Committee, in col-
laboration with the EURObservational Research Programme (EORP)
provided the study design, protocol, and scientific leadership of the regis-
try under the responsibility of the European Heart Rhythm Association
(EHRA) Scientific Initiatives Committee (SIC). The study design has been
discussed in greater detail elsewhere.14
The present investigation was undertaken to assess the efficacy and
safety of TLE in women and men and to compare the clinical and
procedure-related factors that were likely to affect the effectiveness of
TLE in females and males. The following clinical factors were taken into
account: left ventricular ejection fraction (LVEF) and the New York
Heart Association (NYHA) functional class, the presence of arterial hy-
pertension, coronary artery disease, atrial fibrillation, chronic obstructive
pulmonary disease (COPD), diabetes mellitus, malignancy, and renal fail-
ure. Of CIED related factors, we analysed type of implanted devices, indi-
cations for TLE, previous CIED procedures (system changes, revision, or
upgrade), number and type of extracted leads, extraction of abandoned
leads, signs and symptoms of venous occlusion, and tricuspid valve dys-
function before TLE and leads extraction techniques.
Definitions
Transvenous lead extraction, radiological success, clinical success, major
and minor complications were defined according to the 2017 HRS
(Heart Rhythm Society)15 and 2018 EHRA guidelines.16
Lead extraction was defined as any lead removal procedure in which
at least one lead requires the assistance of equipment not typically re-
quired during implantation or at least one lead was implanted for longer
than 1 year.
Radiological success (complete procedural success considered for
each lead) was defined as removal of all targeted leads and material with
the absence of any permanently disabling complication or procedure-
related death.
Clinical success was defined as lead extraction procedures with re-
moval of all targeted leads and lead material from the vascular space or
retention of a small portion of the lead (<4 cm) that does not negatively
impact the outcome goals of the procedure.
Major complications were defined as any of the outcomes related to
the procedure, which is life-threatening or results in death (cardiac or
What’s new?
• Transvenous leads extraction (TLE) in women is characterized
by lower efficacy and a greater number of serious
complications.
• For the first time, different risk factors for TLE in female and
male sex have been documented.
• The main risk factors of TLE in women include: signs and
symptoms of venous occlusion, cumulative leads dwell time,
and number of generator replacements.
• The concept of the leading role of appropriate lead manage-
ment in women has been presented.



































































































non-cardiac) or any complication that causes persistent or significant dis-
ability or requires significant surgical intervention.
Minor complications were defined as any undesired event related to
the procedure that requires medical intervention or minor procedural in-
tervention to remedy and does not limit persistently or significantly the
patient’s function, nor does it threaten life or cause death.
The list of major and minor complications is provided in the
Supplementary material online, Tables S1 and S2.
Intra-procedural complications were defined as any event related to
the performance of the procedure that occurred or became evident
from the time the patient entered the operating room or catheterization
laboratory until the time the patient left the operating room.13
Post-procedural complications were defined as any other such event
occurring after the procedure until patient discharge.
Lead extraction procedure
Leads extraction techniques in ELECTRa population included use of man-
ual traction, locking stylets and sheaths. The sheaths consisted of mechan-
ical non-powered (polypropylene or similar plastic material made) or
powered tools: laser, radio frequency electrosurgical, controlled-
rotational with threaded tip. Other tools, dedicated to other procedures
(pigtail catheters, deflectable wires, deflectable catheters, deflectable
sheaths) were rarely used in this population. The most often approach
was subclavian venous entry, an alternative methods with jugular and
femoral access were rarely used.
Men and women were compared with respect to total procedure du-
ration, fluoroscopy time, lead extraction technique, venue for lead ex-
traction, total number and types of extracted leads, tricuspid valve
function, presence of vegetations, and pericardial effusion. A comparative
analysis of cumulative leads dwell time in females and males was also car-
ried out. Cumulative leads dwell time was calculated as the sum of age of
the extracted leads.
Efficacy and safety of lead extraction
We analysed radiological and clinical success of TLE in women and in
men, and the presence of major and minor complications in both sexes.
Statistical analysis
The statistical analysis was performed using the SAS (tm) software.
Continuous variables were expressed as mean ± standard deviation or as
median and interquartile range (IQR), using the Mann–Whitney test to
compute the P-value of women vs. men regiments. Categorical variables
were expressed as percentages (without missing values if applicable) and
the Fisher’s exact test was used to compute the P-value. The analysis of
relevant factors for major events in man and women was performed with
a univariate logistic regression (SAS PROC LOGISTIC), seeTable 5; only
the factors having a P-value below 5% entered the multivariate analysis,
with a stepwise selection at entry and stay levels of 5%.
Results
The women undergoing TLE were younger than men: 67.0 (IQR
54.0–76.0) vs. 68.0 (IQR 58.0–76.0) years; P=0.0425. They also had
lower body mass index (BMI): 25.92± 5.34 vs. 26.91± 4.49 kg/m2;
P<0.0001 and higher LVEF: 55.0% (IQR 44.0–60.0) vs. 45.0% (IQR
30.0–56.0) and were more likely to be in NYHAClass I–II: 90.11% vs.
86.44; P<0.0001. Men more often had additional diseases: arterial
hypertension, diabetes mellitus, renal failure, COPD, and coronary
artery disease, and they were more likely to receive antiplatelet
agents, also in the periprocedural period. Hypertrophic cardiomyop-
athy and primary electrical disease were more often observed in
women. Moreover, more women had a history of malignancy
(Table 1).
Men more often received complex devices (ICD, CRT-defibrilla-
tor) and underwent generator replacement. Infectious complications
were less common in women. In contrast, both pocket infection and
systemic infection were more frequent in men, which were associ-
ated with a higher number of vegetations and elevated inflammatory
parameters. Number of targeted leads was higher in men, whereas
women were found to have more non-functional, abandoned leads:
46.0% vs. 34.8%; P<0.0001. Cumulative leads dwell time was similar
in both sexes, with a tendency in women towards extracting leads
with implant duration of more than 10 years (21.42% vs. 18.79%;
P=0.0865). Women more often had tricuspid regurgitation (7.65%
vs. 5.23%; P=0.0198) and pericardial effusion (7.91% vs. 4.72%;
P=0.0018) before TLE. Venous complications related to the pres-
ence of leads were also more common in women: 5.97% vs. 4.33%;
P=0.0514 (Table 2).
Female sex was associated with a higher rate of procedure-related
major complications (2.57% vs. 1.30%; P=0.012). The higher fre-
quency of major complications in women vs. men was mainly due to
injury to the heart muscle and large vessels during the procedure,
yielding notably lower rates of radiological and clinical success in
women. The number of minor complications was similar in both
sexes (Table 3, Figure 1).
The majority of leads extracted in women were pacing leads
(84.85% vs. 79.20%; P<0.0001). Defibrillation leads and left ventricu-
lar leads were extracted more often in males than in females (46.93%
vs. 27.63% and 17.06% vs. 10.21%; P<0.0001) (Table 4).
Regarding TLE techniques and approaches, mechanical, non-pow-
ered sheaths were more frequently used in women (49.9% vs.
41.73%; P<0.0001), while in men the powered sheaths were more
often (32.97% vs. 26.16%; P<0.0001) with a predominance of laser
sheaths (23.29% vs. 17.32%; P<0.0001). The majority of patients re-
quired dilatation through the subclavian venous entry site, while alter-
native approaches like femoral or jugular were rarely used with a
comparable frequency in women and men.
Significant tricuspid regurgitation and pericardial effusion after TLE
were more common in women (7.03% vs. 4.65%; P=0.0280 and
12.62% vs. 7.55%; P=0.0002).
Analysis of procedure-related factors also showed that women
more frequently underwent TLE in the cardiac surgery room or hy-
brid operating room than in an electrophysiology room as compared
to men.
In the univariate analysis men and women differed in factors pre-
dicting major complications. In men, the clinical factors such as age,
lower BMI, arterial hypertension, heart failure, and chronic renal fail-
ure were more prevalent. Device infection was another important
risk factor for major complications for men. In women, only high lev-
els of creatinine were confirmed as an important predictor of adverse
outcomes. Of procedure-related factors, a higher number of previ-
ous CIED procedures and more leads with long implant duration in
both sexes, and the oldest target lead dwelling time (>10 years) in
women were identified as predictors of major complications: OR



































































































4.458 (2.139–9.294); P<0.0001. Moreover, signs and symptoms of
venous occlusion identified women at increased risk of adverse out-
comes: OR 4.275 (1.674–10.913); P=0.0024, whereas in men it was
tricuspid regurgitation before TLE: OR 3.410 (1.564–7.434);
P=0.0020, use of powered sheaths: OR 2.593 (1.579–4.259);
P=0.0002, and technical problems during TLE: OR 2.152 (1.267–
3.655); P=0.0046, notably the use of alternative access techniques:
2.543 (1.273–5.081); P=0.0082 (Supplementary material online,
Table S3).
In the multivariate analysis signs and symptoms of venous occlu-
sion, cumulative leads dwell time and the number of generator
replacements were the main risk factors for major complications in
....................................................................................................................................................................................................................
Table 1 Clinical characteristics of women and men undergoing TLE
Variables Women (N5 971) Men (N5 2539) P-value
Number, n (%) 971 (27.66%) 2539 (72.33%)
Age (years)
Mean (SD) 63.29 (17.73) 65.49 (14.69)
Median (IQR) 67.00 (54.00–76.00) 68.00 (58.00–76.00) 0.0425
Age >_65 years, n/N (%) 541/971 (55.72%) 1513/2539 (59.59%) 0.0387
Race (Caucasian), n/N (%) 821/848 (96.82%) 2067/2136 (96.77%) 1.0000
Mean BMI (kg/m2), n 952 2480
Mean (SD) 25.92 (5.34) 26.91 (4.49)
Median (IQR) 25.30 (22.45–28.85) 26.30 (24.10–29.40) <0.0001
LVEF, n 913 2389
Mean (SD) 51.00 (13.11) 43.43 (14.72)
Median (IQR) 55.00 (44.00–60.00) 45.00 (30.00–56.00) <0.0001
LVEF <_35%, n/N (%) 162/913 (17.74%) 899/2389 (37.63%) <0.0001
NYHA Class I and II, n/N (%) 875/971 (90.11%) 2149/2539 (84.64%) <0.0001
NYHA Class III and IV, n/N (%) 96/971 (9.89%) 390/2539 (15.36%) <0.0001
Sinus node disease, n/N (%) 282/659 (42.79%) 431/1189 (36.25%) 0.0061
A-V block, n/N (%) 344/659 (52.20%) 686/1189 (57.70%) 0.0245
CAD, n/N (%) 216/967 (22.34%) 1159/2515 (46.08%) <0.0001
VHD, n/N (%) 159/971 (16.37%) 355/2529 (14.04%) 0.0878
DCM, n/N (%) 173/967 (17.89%) 744/2525 (29.47%) <0.0001
HCM, n/N (%) 60/969 (6.19%) 98/2533 (3.87%) 0.0046
CHD, n/N (%) 58/971 (5.97%) 68/2530 (2.69%) <0.0001
Previous sternotomy, n/N (%) 125/971 (12.87%) 471/2533 (18.59%) <0.0001
Primary electrical disease, n/N (%) 295/965 (30.57%) 655/2518 (26.01%) 0.0074
Hypertension, n/N (%) 502/966 (51.97%) 1386/2512 (55.18%) 0.0945
DM, n/N (%) 176/968 (18.18%) 605/2519 (24.02%) 0.0002
Chronic kidney disease, n/N (%) 123/967 (12.72%) 490/2526 (19.40%) <0.0001
COPD, n/N (%) 60/968 (6.20%) 237/2515 (9.42%) 0.0022
Malignancy treatment, n/N (%) 13/971 (1.34%) 4/2539 (0.16%) <0.0001
Anticoagulation preoperatively, n 971 2539
Mean (SD) 0.36 (0.48) 0.37 (0.48)
Median (IQR) 0.00 (0.00–1.00) 0.00 (0.00–1.00) 0.4265
Antiplatelet therapy preoperatively, n/N (%) 262/971 (26.98%) 1151/2539 (45.33%) <0.0001
ASA, n/N (%) 246/971 (25.33%) 1042/2539 (41.04%) <0.0001
Clopidogrel, n/N (%) 27/971 (2.78%) 177/2539 (6.97%) <0.0001
ASA þ Clopidogrel, n/N (%) 15/971 (1.54%) 90/2539 (3.54%) 0.0012
Laboratory tests: WBC count, n 889 2307
Mean (SD) 7.71 (2.96) 7.77 (2.90)
Median (IQR) 7.00 (5.80–8.78) 7.29 (6.00–8.90) 0.0980
Laboratory tests: CRP, n 764 1960
Mean (SD) 16.71 (41.86) 17.96 (43.51)
Median (IQR) 3.06 [(1.00–10.45) 4.00 (1.04–12.80) 0.0234
ASA, Aspirin; BMI, body mass index; CAD, coronary artery disease; CHD, congenital heart disease; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein;
DCM, dilated cardiomyopathy; DM, diabetes mellitus; HCM, hypertrophic cardiomyopathy; IQR, interquartile range; LVEF, left ventricular ejection fraction; NYHA, New York
Heart Association; SD, standard deviation; VHD, valvular heart disease; WBC, white blood cell.



































































































women (Figure 2, Table 5). In men, the number of leads, use of pow-
ered sheaths, lower BMI, and high white blood cell count were identi-
fied as predictors of adverse outcomes (Figure 3, Table 5).
Discussion
Several investigations, including preliminary analysis of the
ELECTRa Registry show that female sex is an independent predic-
tor of periprocedural complications of TLEs,9,11–13,17 however, a
few studies found no difference in risk of adverse outcomes of TLE
in women vs. men.18,19 This discrepancy can result from differences
in the treated population and lead extraction techniques. The pre-
sent study confirmed that major complications associated with in-
jury to the myocardium and large veins, and tricuspid dysfunction
were more common in women. Previous reports have not investi-
gated specific risk factors for TLE in female and male sexes. The
current analysis of a large population of the ELECTRa registry (971
women) showed the difference in the factors determining the ef-
fectiveness and safety of TLE in women and men. The main risk
factors for the complications of TLE in women were: signs and
symptoms of venous occlusion, cumulative leads dwell time, and
the number of generator replacements. More frequent occurrence
of venous occlusion in the female sex together with a large impact
of this factor on the risk of TLE confirms earlier hypotheses re-
garding the reasons of worse effects of procedures in women.
According to previous studies, potential causes of increased
procedure-related risk in women include lower BMI, small sizes of
the vessels, and thinner walls of the myocardium and veins.20 More
vigorous lead ingrowth has also been suggested in women.21
Venous occlusion is strictly connected with the next risks factors
demonstrated in the present study. Lead dwell time is commonly
known factor affecting the possibility of complications during
TLE.18,22–25 Similarly, the number of previous generator exchanges
....................................................................................................................................................................................................................
Table 2 Comparison of CIED, lead characteristics, and procedural indications to TLE between women and men
Variables Women (N5 971) Men (N52539) P-value
PM, n/N (%) 659/971 (67.87%) 1189/2539 (46.83%) <0.0001
ICD, n/N (%) 310/971 (31.93%) 1345/2539 (52.97%) <0.0001
CRT-P, n/N (%) 34/971 (3.50%) 93/2539 (3.66%) 0.9195
CRT-D, n/N (%) 98/971 (10.09%) 508/2539 (20.01%) <0.0001
Number of previous system revisions, n 971 2539
Mean (SD) 1.07 (7.79) 1.71 (10.86)
Median (IQR) 0.00 (0.00–1.00) 0.00 (0.00–1.00) 0.0550
Number of generator replacements, n 971 2539
Mean (SD) 1.01 (6.38) 1.41 (8.74)
median (IQR) 0.00 (0.00–1.00) 0.00 (0.00–1.00) 0.0053
Infective indications for TLE, n/N (%) 413/969 (42.62%) 1452/2530 (57.39%) <0.0001
Local, pocket infection, n/N (%) 248/969 (25.59%) 922/2530 (36.44%) <0.0001
Systemic infection, n/N (%) 160/969 (16.51%) 520/2530 (20.55%) 0.0065
Non-infective indications for TLE, n/N (%) 558/971 (57.47%) 1087/2539 (42.81%) <0.0001
Presence of vegetations, n/N (%) 136/408 (33.33%) 442/1036 (42.66%) 0.0013
Tricuspid valve regurgitation before TLE, n/N (%) 60/784 (7.65%) 104/1990 (5.23%) 0.0198
Pericardial fluid before TLE, n/N (%) 62/784 (7.91%) 94/1990 (4.72%) 0.0018
Number of targeted leads, n 971 2539
Mean (SD) 1.71 (0.77) 1.89 (0.90)
Median (IQR) 2.00 (1.00–2.00) 2.00 (1.00–2.00) <0.0001
Leads dwell time (months), n 965 2522
Mean (SD) 7.30 (6.35) 6.71 (5.32)
Median (IQR) 6.00 (3.00–9.00) 6.00 (3.00–9.00) 0.2787
Oldest target lead dwell time >10 years, n/N (%) 208/971 (21.42%) 477/2539 (18.79%) 0.0865
Cumulative leads dwell time, n 964 2521
Mean (SD) 11.88 (11.97) 11.86 (11.18)
Median (IQR) 8.00 (4.00–16.00) 8.00 (4.00–16.00) 0.4300
Patients with target ICD lead, n/N (%) 268/970 (27.63%) 1189/2538 (46.85%) <0.0001
Presence of non-functional leads, n/N (%) 447/971 (46.04%) 884/2539 (34.82%) <0.0001
Presence of thrombosis or venous stenosis, n/N (%) 54/971 (5.56%) 106/2539 (4.17%) 0.0855
Signs and symptoms of venous occlusion, n/N (%) 58/971 (5.97%) 110/2539 (4.33%) 0.0514
CIED, cardiac implantable electronic devices; CRT-D, cardiac resynchronization therapy-defibrillator; CRT-P, cardiac resynchronization therapy-pacemaker; ICD, implantable
cardioverter-defibrillator; IQR, interquartile range; PM, pacemaker; SD, standard deviation; TLE, transvenous leads extraction.



































































































is directly related to the age of the leads. The present findings doc-
umenting increased risk associated with cumulative leads dwell
time and venous occlusion seem to confirm the concept of the
smaller sizes of the vessels with stronger adhesion of the oldest
leads to the walls of the thinner veins in females.
Generally, the population of women undergoing TLE is definitely
lower than men, ranging from 15% to 39.3% in the available
reports,12,26 being 27.66% in the ELECTRa Registry. Probably, the
next reason of worse efficacy of TLE with greater number of peripro-
cedural complications could be a different lead management strategy
in female patients with tendency to abandonment of the leads.2,7
Presence of more non-functional abandoned leads (46.04% vs.
34.82%; P<0.001) together with a tendency for extracting leads that
have been implanted for more than 10 years (21.42% vs. 19.79%;
P=0.0865) indicates that female patients were referred for TLE at a
later time, after choosing first a lead abandonment strategy. For this
reason, leads with the longest dwell times (above 10 years) were
....................................................................................................................................................................................................................
Table 3 Safety and efficacy of TLE in women and men
Variables Women (N5 971) Men (N5 2539) P-value
MAJOR complications related to TLE, n/N (%) 25/971 (2.57%) 33/2539 (1.30%) 0.012
Intra procedural MAJOR complications, n/N (%) 19/971 (1.96%) 18/2539 (0.71%) 0.0025
Post-procedural MAJOR complication, n/N (%) 11/971 (1.13%) 47/2539 (1.85%) 0.1817
MAJOR complication death, n/N (%) 11/28 (39.29%) 39/60 (65.00%) 0.0368
Cause of death cardio or vascular, n/N (%) 5/971 (0.51%) 23/2539 (0.91%) 0.2940
Cardiac avulsion or tear requiring sternotomy, thoracotomy, pericardio-
centesis, chest tube, or surgical repair, n/N (%)
15/971 (1.54%) 15/2539 (0.59%) 0.0120
Vascular avulsion or tear, n/N (%) 10/971 (1.03%) 11/2539 (0.43%) 0.0500
Pulmonary embolism requiring surgical intervention, n/N (%) 0/971 (0.00%) 0/2539 (0.00%)
Respiratory arrest or anaesthesia related complications leading to prolon-
gation of hospitalization, n/N (%)
2/971 (0.21%) 7/2539 (0.28%) 1.0000
Pacing system related infection of a previously non-infected site, n/N (%) 0/28 (0.00%) 0/61 (0.00%)
Stroke, n/N (%) 0/28 (0.00%) 4/61 (6.56%) 0.3040
MINOR complications, n/N (%) 46/74 (62.16%) 134/192 (69.79%) 0.2447
Intra-procedural MINOR complications, n/N (%) 11/971 (1.13%) 24/2539 (0.95%) 0.5751
Post-procedural MINOR complications, n/N (%) 11/971 (1.13%) 24/2539 (0.95%) 0.5751
Pericardial effusion not requiring pericardiocentesis or surgical interven-
tion, n/N (%)
6/46 (13.04%) 23/128 (17.97%) 0.4988
Hemothorax not requiring a chest tube, n/N (%) 0/46 (0.00%) 3/128 (2.34%) 0.5667
Haematoma at the surgical site requiring reoperation for drainage, n/N (%) 10/46 (21.74%) 30/128 (23.44%) 1.0000
Arm swelling or thrombosis of implant veins resulting in medical interven-
tions, n/N (%)
9/46 (19.57%) 20/128 (15.63%) 0.6448
Vascular repair near the implant site or venous entry site, n/N (%) 0/46 (0.00%) 3/128 (2.34%) 0.5667
Haemodynamically significant air embolism, n/N (%) 0/46 (0.00%) 0/128 (0.00%)
Migrated lead fragment without sequelae, n/N (%) 1/46 (2.17%) 4/128 (3.13%) 1.0000
Blood transfusion related to blood loss during surgery, n/N (%) 10/46 (21.74%) 16/128 (12.50%) 0.1504
Pneumothorax requiring a chest tube, n/N (%) 5/46 (10.87%) 7/128 (5.47%) 0.3056
Pulmonary embolism not requiring surgical intervention, n/N (%) 6/46 (13.04%) 10/128 (7.81%) 0.3711
Tip of the lead remained, n/N (%) 52/970 (5.36%) 110/2538 (4.33%) 0.2079
Fragment of the lead (less than 4 cm remained), n/N (%) 25/970 (2.58%) 47/2538 (1.85%) 0.1837
Radiological success of TLE, n/N (%) 934/970 (96.29%) 2488/2538 (98.03%) 0.0046
Clinical success of TLE, n/N (%) 952/970 (98.14%) 2518/2538 (99.21%) 0.0098































(P = 0 0046)
96,29%
98,03%Men
Figure 1 Individual radiological and clinical success and major
complications in men and women.




































































































Table 4 TLE-procedure and post-procedure information
Variables Women (N5 971) Men (N5 2539) P-value
Total leads removed, n 971 2539
Mean (SD) 1.70 (0.79) 1.88 (0.90)
Median (IQR) 2.00 (1.00–2.00) 2.00 (1.00–2.00) <0.0001
Pacing (PM) leads extracted, n/N (%) 823/970 (84.85%) 2010/2538 (79.20%) 0.0001
PM atrial leads extracted, n/N (%) 577/970 (59.48%) 1542/2538 (60.76%) 0.5118
PM ventricular leads extracted, n/N (%) 832/970 (85.77%) 2349/2538 (92.55%) <0.0001
High voltage (HV) leads extracted, n/N (%) 268/970 (27.63%) 1191/2538 (46.93%) <0.0001
Coronary sinus (CS) leads extracted, n/N (%) 99/970 (10.21%) 433/2538 (17.06%) <0.0001
Total procedure time (min), n 946 2457
Mean (SD) 96.40 (62.71) 96.36 (61.68)
Median (IQR) 80.00 (55.00–120.00) 83.00 (58.00–120.00) 0.7187
Total fluoroscopic time (min), n 933 2368
Mean (SD) 13.41 (16.17) 13.81 (17.12)
Median (IQR) 9.00 (4.09–16.00) 9.00 (4.00–17.46) 0.9343
Locking stylets used, n/N (%) 688/970 (70.93%) 1863/2538 (73.40%) 0.1496
Sheaths used, n/N (%) 363/970 (37.42%) 1107/2538 (43.62%) 0.0009
Mechanical non-powered sheath used, n/N (%) 484/970 (49.90%) 1059/2538 (41.73%) <0.0001
Powered sheath used, n/N (%) 254/971 (26.16%) 837/2539 (32.97%) <0.0001
Laser sheath used, n/N (%) 168/970 (17.32%) 591/2538 (23.29%) 0.0001
Evolution
VR
mechanical dilator sheath used, n/N (%) 87/970 (8.97%) 245/2538 (9.65%) 0.5621
Electrosurgical dissection sheath used, n/N (%) 0/970 (0.00%) 5/2538 (0.20%) 0.3313
Other tools used, n/N (%) 4/970 (0.41%) 5/2538 (0.20%) 0.2725
Lead removed with traction alone, n/N (%) 309/960 (32.19%) 882/2503 (35.24%) 0.0934
Alternate approach required, n/N (%) 57/970 (5.88%) 175/2538 (6.90%) 0.2887
Technical issues during extraction, n/N (%) 177/970 (18.25%) 470/2538 (18.52%) 0.8840
TLE in operating room, n/N (%) 546/971 (56.23%) 1278/2539 (50.33%) 0.0020
TLE in hybrid room, n/N (%) 110/971 (11.33%) 225/2539 (8.86%) 0.0289
Tricuspid valve regurgitation grade III-IV after TLE, n/N (%) 44/626 (7.03%) 80/1722 (4.65%) 0.0280
Pericardial fluid after TLE, n/N (%) 79/626 (12.62%) 130/1722 (7.55%) 0.0002
IQR, interquartile range; SD, standard deviation; TLE, transvenous leads extraction.
....................................................................................................................................................................................................................
Table 5 Multivariate logistic regression after stepwise algorithm selection—events: major complications in women
and men
Covariables Reference level Class level OR 95% CI P-value
Major complications in women
Number of generator replacements No Yes 1.029 1.005–1.054 0.0184
Signs and symptoms of venous occlusion No Yes 3.730 1.401–9.934 0.0084
Cumulative leads dwell time – – 1.044 1.024–1.065 <0.0001
Major complications in men
Mean BMI (kg/m2) No Yes 0.891 0.818–0.970 0.0077
Laboratory tests: WBC count No Yes 1.178 1.102–1.259 <0.0001
Number of targeted leads No Yes 6.053 2.422–15.129 0.0001
Total leads removed No Yes 0.287 0.118–0.695 0.0057
Powered sheath used No Yes 2.742 1.404–5.355 0.0031
CI, confidence interval; OR, odds ratio; WBC, white blood cell.



































































































found in the female population, and the underlying causes of fewer
extraction procedures and related complications were more com-
plex. This theory is confirmed by the strong influence of cumulative
leads dwell time on the occurrence of major complications of TLE in
women.
The analysis of TLE risk factors in men has demonstrated that in
males, the number of leads and use of powered sheaths appeared to
increase the risk of developing major complications during or after
TLE. Evidence shows that the use of more aggressive extraction tech-
niques, especially laser technique may be the cause of more compli-
cations, especially associated with large vessel injury.18,26 It should be
emphasized that the present study demonstrated lower efficacy and
more major complications in women despite less frequent use of
powered sheaths, extracting fewer leads, and better protection dur-
ing the procedure under the direct supervision of cardiac surgeons. It
means that the impact of sex-specific risk factors is strong and always
should be taken into consideration when choosing the appropriate
lead management strategy in women.
The risk of TLE in men from the ELECTRa population was also as-
sociated with elevated white blood cells counts. The effect of this fac-
tor has already been identified in previous reports10,22 and is related
to the severe course of infection The problem of CIED related infec-
tions in women and men is complex, because this complications are
more likely to occur in the male sex,8,17,27–31 however, some studies
documented worse clinical course of infections in women with more
often presence of vegetations and higher mortality of females.32,33
Furthermore, more frequent infectious indications for TLE in male
sex contribute to more effective removal of younger leads in men.
Current analysis seems to confirm these considerations.
In summary, the reasons for less effective TLE in women are com-
plex and involve different risk factors for the procedure. Due to
worse anatomical conditions (smaller size of the vessels, thinner
heart walls) and documented impact of cumulative leads dwell time
on the risk of TLE in females, the proper leads management is very
important and the procedures in women should be performed in
high-volume centres, in the hybrid room and by the most experi-
enced operators.
Limitations
ELECTRa is an international registry whose results are developed
post hoc, which is associated with some limitations. Despite moni-
toring the data reliability and database quality control there was a




Multivariate logistic regression after stepwise algorithm
selection - events : Major complication women (odd ratio)
Number of generator
replacements 1029 [1005;1054]
(P = 0 0184)
Cumulative dwell time (months)
1044 [1024-1065] (P <0 0001)
Signs and symptoms of venous
occlusion 3730 [1401;9934]




























5355] P = 0 0031
Total leads removed
0287 [0118; 0695]
P = 0 0057
Number of targeted
leads 6053 [2422;
15 129] P = 0 0001
Multivariate logistic regression after stepwise algorithm
selection - events : Major complication men (odd ratio)
Figure 3 Significant risk factors of major complications in men—multivariate logistic regression.



































































































The data collected in the register concern only patients who have
completed the TLE procedure. There is no possibility to compare
the patients’ data with the indications for TLE in which the procedure
was not performed.
Conclusions
The effectiveness of TLE in women was lower than in men, and the
risk of complications was associated with other factors in the female
and male sex. The main predictors of increased risk of major compli-
cations in women are factors influenced on strongly ingrown of the
leads to the walls of the veins and myocardium. The initial manage-
ment strategy with lead abandonment may increase the risk of the
later leads extraction in women.
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Supplementary material is available at Europace online.
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